| Record ID | marc_records_scriblio_net/part24.dat:66170017:1164 |
| Source | Scriblio |
| Download Link | /show-records/marc_records_scriblio_net/part24.dat:66170017:1164?format=raw |
LEADER: 01164cam 22003378a 4500
001 94031798
003 DLC
005 19970519181006.5
008 940726s1994 xxc b 000 0 eng c
010 $a 94031798
020 $a0919839282 (pbk.)
040 $aDNLM/DLC$cDLC$dDLC
050 00 $aRC115$b.T48 1994
060 10 $aQV 350 T3975 1994
082 00 $a616/.014$220
245 00 $aTherapeutic implications of treatment with beta-lactamase inhibitor combinations /$ceditor, Robert Moellering, Jr.
260 $aMontreal ;$aChicago :$bPharmaLibri Publishers,$c1994.
263 $a9410
300 $ap. cm.
490 1 $aPharmanual
504 $aIncludes bibliographical references.
650 00 $aBeta lactamases$xInhibitors$xTherapeutic use.
650 00 $aBacterial infections$xChemotherapy.
650 00 $aDrug resistance in microorganisms.
650 2 $aAntibiotics, Lactam$xtherapeutic use.
650 2 $aAntibiotics, Lactam$xpharmacology.
650 2 $abeta-Lactamases$xantagonists & inhibitors.
650 2 $aDrug Therapy, Combination.
650 2 $aDrug Resistance, Microbial.
700 1 $aMoellering, Robert C.
830 0 $aPharmanual (Chicago, Ill.